Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

V, Santini; D, Valcárcel; U, Platzbecker; RS, Komrokji; AL, Cleverly; MM, Lahn; J, Janssen; Y, Zhao; A, Chiang; A, Giagounidis; SC, Guba; I, Gueorguieva; AC, Girvan; Silva Ferreira M, da; TD, Bhagat; K, Pradhan; U, Steidl; A, Sridharan; B, Will; A, Verma

doi:10.1158/1078-0432.ccr-19-1338

Public

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Shared by NobleBlocks on Sep 3, 2019 • 12:00 AM UTC

Authors:

Santini V

Valcárcel D

Platzbecker U

Abstract

Purpose Overactivation of TGF-β signaling is observed in myelodysplastic syndromes (MDS) and is associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor of the TGF-β receptor type 1 kinase (ALK5) has shown effectiveness in preclinical models of MDS and ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!